Evalyze v1.3.0 is a related product worth comparing with PropelRx.
PropelRx
PropelRx · US-based
PropelRx is a fundraising readiness platform built for Seed to Series B founders preparing for institutional investor outreach.
PropelRx is a fundraising readiness platform built for Seed to Series B founders preparing for institutional investor outreach.
Mindber Score™
Score pending - additional data required
Mindber Score™
Score pending - additional data required
Starting price
Pricing unverified
Best for
Free instagram private profi…
Free trial
✓ Free tier
Explore options
See how PropelRx compares
PropelRx is a practical fit for buyers evaluating focused AI tooling.
- Pricing
- freemium
- Alternatives
- Evalyze v1.3.0,Finta,Raizer
Product information
What this product does
PropelRx is a fundraising readiness platform built for Seed to Series B founders preparing for institutional investor outreach. Unlike investor databases or fundraising CRMs, PropelRx assesses whether a founder is structurally ready to raise — before they approach a single investor. It evaluates narrative coherence, financial model integrity, pitch material quality, and capital positioning against institutional standards. The platform produces a Capital Readiness Score across 8 dimensions and a prioritised action plan — so founders raise when they're ready, not when they're eager. Key capabilities: - Fundraising readiness assessment - Capital readiness scoring - Narrative and materials evaluation - Investor-fit signal analysis - Structured fundraising workflow management - Fundraising execution tracking PropelRx is the infrastructure layer that sits before investor outreach begins. It tells founders whether to raise, when to raise, and exactly what needs to change first. Built for founders who treat fundraising as a structured execution process, not a volume game. AgentsAPI Ai-powered Investor MatchingAifa – Fundraising Execution AssistantAtlas – Investor Discovery AgentLuna – Pitch & Communication CoachAi Cfo – Financial Strategy AgentSignal-based Investor FilteringStructured Fundraising WorkflowOutreach & Engagement TrackingInvestor Fit ScoringFundraising Pipeline ManagementFounder-friendly InterfaceSeed To Series B Focus
Sourced from propelrx.ai
Works With
Platforms
- Web
- iOS
Company & Maker
Who built PropelRx?
- Product
- PropelRx is a fundraising readiness platform built for Seed to Series B founders preparing for institutional investor outreach. Unlike investor databases or fundraising CRMs, PropelRx assesses whether a founder is structurally ready to raise — before they approach a single investor. It evaluates ...
- HQ
- US
- Live since
- Feb 2026
- Makers
- Jamal Hirani - Building AI-powered tools for founders. Founder of PropelRx and Propeligent — f… Profile

Building AI-powered tools for founders. Founder of PropelRx and Propeligent — focused on structured fundraising and capital readiness.
See It In Action
Does PropelRx have a demo?
Yes — watch the walkthrough below.
Researched with AI · Data refreshed 5 months ago · How we score
Pricing reality
Verified May 2026 / Vendor pricing evidence only
Starting price
Pricing unverified
Free tier reported; paid-plan amounts are not verified yet.
Mindber only shows named plan cards when they come from linked pricing evidence. If the tier data is incomplete, this page falls back to the verified starting price instead of fabricating plan names or $0 tiers.
What pricing pages often hide
True cost for your case
LIVE ESTIMATEEstimated spend
--Starting price has not been verified from a linked pricing source yet.
Compare this product in-line
Start with a suggested alternative or type another tool to jump into a side-by-side comparison.
RELATED PRODUCTS
Suggested from linked alternativesFinta is a comprehensive AI-powered platform designed to streamline fundraising and investor relations for businesses. The tool features a secure and shareable deal room, where companies can include all the necessary documents and information for investor diligence. The functionalities of Finta exte...
Raizer is an AI-powered platform dedicated to connecting startup founders and investors. It enhances the funding process by providing startup founders with a tool to raise capital effectively, while granting investors access to select startup deals. Users have the ability to set up a verified startu...
Activity signals
Insufficient data
Only 6 of 5 minimum public signals linked. Score appears once we collect 0 more independent signals.
Traffic & search proof
Public view keeps the ratio story. Paid view unlocks exact monthly visits, full region coverage, and CPC-level keyword intelligence.
Google Trends live interest
Live Google Trends data for PropelRx: interest over time, regions, topics, and related queries.
Tracks 12-month Google search interest on a 0-100 relative interest scale.
Includes regional demand, so readers can see where search interest is strongest.
Includes related topics and related queries to surface adjacent demand and search intent.
FAQ
Only linked Q and A rows are shown. Empty FAQ data stays hidden.
Sources and methodology
Only evidence with a linked source record or explicit feature provenance is shown here. Data without provenance stays off the page.
COMMUNITY CREDITS
Have you used PropelRx? Earn credits.
Verified contributions help the page stay honest. The wider member action set still lives in your dashboard so the public page stays focused on the two highest-signal workflows.
Write a verified review (200+ words) → earn 1 credit
Share the setup context, what worked, and what broke. Mindber rewards specific, evidence-backed reviews instead of one-line praise.
Write verified reviewSpot incorrect data? Submit a correction → earn 1 credit
Flag stale pricing, wrong traffic signals, or broken links and the editorial team will re-verify the record.
Submit correctionMaker access, comments, ratings, and verification requests remain available inyour dashboard.
Community audits
Member opinion — not a Mindber assessment
Be the first to audit PropelRx
No member audits yet. Rate it from 1 to 5 and share what worked and what didn't.